The Rising Tide of Antimicrobial Resistance

Antibiotic resistance occurs when bacteria evolve to withstand the effects of drugs designed to kill them. This phenomenon, a natural process, is accelerated by the overuse and misuse of antibiotics. Gonorrhoea, notorious for its ability to adapt, has historically demonstrated a capacity to develop resistance to multiple drugs. The current trend, however, represents a significant acceleration of this process.

EGASP, established in 2015, plays a crucial role in monitoring these changes. By collecting and analyzing laboratory and clinical data from sentinel sites globally, the program provides vital insights into the spread of drug-resistant strains and informs the development of effective treatment guidelines. The program’s expansion, now encompassing 12 countries across five WHO regions – Brazil, Cambodia, India, Indonesia, Malawi, the Philippines, Qatar, South Africa, Sweden, Thailand, Uganda, and Viet Nam – is a positive step, reflecting a growing commitment to tackling this challenge.

Alarming Trends in Antibiotic Resistance

Between 2022 and 2024, resistance to ceftriaxone and cefixime – the primary antibiotics used to treat gonorrhoea – experienced a dramatic increase. Resistance to ceftriaxone jumped from 0.8% to 5%, while resistance to cefixime nearly tripled, rising from 1.7% to 11%. While resistance to azithromycin remained relatively stable at 4%, resistance to ciprofloxacin has reached a staggering 95%. Cambodia and Viet Nam are currently reporting the highest rates of resistance, highlighting the urgent need for targeted interventions in these regions.

The WHO’s Director of the Department for HIV, TB, Hepatitis & STIs, Dr. Tereza Kasaeva, emphasized the critical importance of this global effort: “This global effort is essential to tracking, preventing, and responding to drug-resistant gonorrhoea and to protecting public health worldwide.” The WHO is urging all countries to prioritize the surveillance of STIs and integrate gonorrhoea monitoring into their national public health programs.

Geographic Distribution and Patient Demographics

Data from 2024 reveals a concerning geographic pattern. Over half (52%) of symptomatic gonorrhoea cases in men were reported from the WHO Western Pacific Region, with the Philippines accounting for 28% of these cases, followed by Viet Nam (12%), Cambodia (9%), and Indonesia (3%). The WHO African Region contributed 28% of cases, while South-East Asia, the Eastern Mediterranean, and the Americas accounted for 13%, 4%, and 2% respectively.

The median age of patients diagnosed with gonorrhoea was 27 years, ranging from 12 to 94. A significant proportion of cases (20%) involved men who have sex with men, and a substantial 42% of individuals reported having multiple sexual partners within the past 30 days. Recent antibiotic use was reported by 8% of patients, and 19% had travelled recently, suggesting potential links to antibiotic exposure and international spread.

New Research and Potential Solutions

The WHO is actively pursuing innovative strategies to combat this growing threat. Genomic surveillance, with nearly 3000 samples sequenced from eight countries in 2024, is providing crucial insights into the genetic evolution of the bacteria. Furthermore, research is underway to evaluate the effectiveness of new treatments, including zoliflodacin and gepotidacin. Studies conducted by the WHO’s Collaborating Centre on AMR in STI in Sweden are also exploring the potential of doxycycline-based prevention strategies (DoxyPEP).

Did You Know?

The expansion of EGASP to include Brazil, Côte d’Ivoire, and Qatar, with India set to join in 2025, demonstrates a growing global commitment to surveillance. However, challenges remain, including limited funding, incomplete data reporting, and gaps in information regarding infections in women and at extragenital sites.

What role do you think public health education campaigns should play in curbing the spread of antibiotic resistance? And how can we ensure equitable access to new treatments for all populations affected by gonorrhoea?

The WHO is calling for urgent investment in national surveillance systems to sustain and expand global monitoring efforts. Addressing this escalating crisis requires a concerted, collaborative approach involving governments, healthcare professionals, and individuals alike.

Read the full WHO report here. For more information on antimicrobial resistance, visit the World Antimicrobial Resistance (AMR) Awareness Week website.

Further resources on gonorrhoea and STIs can be found at the Centers for Disease Control and Prevention (CDC) and the National Health Service (NHS).

Frequently Asked Questions About Gonorrhoea and Antibiotic Resistance

1. What is antibiotic resistance in the context of gonorrhoea? Antibiotic resistance occurs when the bacteria that cause gonorrhoea evolve and become less susceptible to the drugs used to treat the infection, making treatment more difficult.
2. How does the WHO’s EGASP program help combat gonorrhoea resistance? EGASP monitors the spread of drug-resistant gonorrhoea strains globally, providing data to inform treatment guidelines and public health interventions.
3. What are the primary antibiotics currently used to treat gonorrhoea, and are they still effective? Ceftriaxone and cefixime are currently the primary antibiotics, but resistance to these drugs is increasing, raising concerns about their long-term effectiveness.
4. What factors contribute to the rise of antibiotic resistance in gonorrhoea? Overuse and misuse of antibiotics, as well as the bacteria’s natural ability to adapt, contribute to the development of antibiotic resistance.
5. What can individuals do to help prevent the spread of gonorrhoea and antibiotic resistance? Practicing safe sex, getting tested regularly for STIs, and using antibiotics only when prescribed by a healthcare professional are crucial steps.
6. Is gonorrhoea resistance a global problem? Yes, gonorrhoea resistance is a growing global health threat, with increasing rates reported in multiple regions worldwide.